WOBURN, Mass., Feb. 22, 2011 /PRNewswire/ — MedTrust Online
(MedTrust) and Avantra Biosciences (Avantra) announced today a
novel collaboration to involve clinicians in the earliest stages of
molecular diagnostic assay development for Avantra Biosciences’
revolutionary QPDx™ multiplex immunoassay system.
The two companies will provide a global community of over 10,000
cancer care professionals with early access to the latest panels of
protein biomarkers implicated in different cancers. Avantra,
based in Woburn, MA, is a leading innovator in protein diagnostics
and recently announced the commercialization of the new Q400
Biomarker Workstation and innovative AngioGenQx™ BioChip
immunoassay. The system provides quantitative protein
biomarker results for ten analytes in less than an hour, requiring
only five minutes for sample preparation.
As Avantra’s scientific development team identifies biomarkers
of interest for its QPDx™ system, MedTrust will use its
Knowledge Medicine™ platform to engage oncologists in online
discussions that will validate the role of different panels in
diagnosis, prognosis, and treatment efficacy in cancer care.
The first of several multiplex assays to be evaluated include
an upcoming panel developed in the recently announced collaboration
between Avantra and TGen Drug Development. Avantra intends to
develop additional panels that may target ovarian, pancreatic,
lung, prostate, breast, and colorectal cancers to uncover
associations between protein marker levels and patient drug
responses that can positively impact clinical decisions.
Currently available for research use only (RUO), Avantra intends to
seek regulatory approval for its assay technologies as the clinical
utility of the molecular information becomes evident. In
addition to oncology, Avantra is exploring opportunities in other
areas such as infectious disease through its upcoming panel for
sepsis.
‘/>”/>
